UrologyDr. Shafiq AhmadProstate Cancer

Senior Director - Urology, Andrology & Renal Transplant, BLK-Max Super Speciality Hospital, New Delhi, India

Part 11 of 17 in Diagnosis and Management of Prostate Cancer

Getting a Second Opinion for Prostate Cancer From India

August 7, 2026

Doctors treating suspected or confirmed prostate cancer patients outside India can access a structured second opinion pathway, sharing case files with specialists in India before deciding whether a patient needs to travel for prostate cancer treatment.

How Does the Second Opinion Process Work?

Referring doctors first assess whether a case meets the complexity criteria that warrant specialist input, then share the relevant reports so the case can be reviewed remotely by the treating team in India. This structured process, sometimes called an online OPD or connect clinic model, helps ensure that only genuinely complex prostate cancer cases requiring specialist attention proceed to a full consultation.

What Happens Once a Case Is Reviewed?

Once a case is confirmed to need specialist attention, a video consultation can be arranged between the specialist in India and the patient, with the local doctor invited to join, so the patient benefits from combined expertise without needing to travel unnecessarily. This collaborative model is designed to bridge the geographical barrier between local doctors and specialists such as Dr. Shafiq Ahmad.

Why Does This Matter for Prostate Cancer Patients?

This structured second opinion pathway allows patients to access expert guidance on prostate cancer diagnosis and treatment in India before committing to travel, helping ensure that a visit is genuinely warranted and that the local doctor remains involved in ongoing care. For prostate cancer in particular, where accurate staging and treatment choice are critical, this kind of specialist input can significantly change a patient's outlook.

← Why Prostate Cancer Patients Are Treated Surgically Even With Advanced Disease | Series index

This article is based on a Jivo Masterclass session conducted by Dr. Shafiq Ahmad, Senior Director, Urology, Andrology and Renal Transplant, BLK-Max Super Speciality Hospital, New Delhi, India. The article has been summarised with the assistance of an AI tool from the original masterclass recording. Watch the full Masterclass recording

This guide is based on a live Jivo Masterclass — Dr. Shafiq Ahmad taught doctors across Africa on July 6, 2025.

FROM THE LIVE Q&A

DR

Dr. William Gataga

How effective is HIFU (high-intensity focused ultrasound) in early-stage prostate cancer?

SA

Dr. Shafiq Ahmad

In our country this facility is not widespread and is not yet widely accepted by the urology community here, though it is practised in the West by urologists, medical oncologists, and interventional radiologists. I would add that prostate cancer is usually slow-growing, but the prostate also has BPH growing alongside it, and patients with even locally advanced or oligometastatic disease often die from the obstructive mass effect of the prostate on the bladder neck and ureters rather than from the cancer itself — which is why, as a surgeon, I usually still consult even locally advanced or oligometastatic candidates for robotic radical prostatectomy, aiming for clear margins, early continence, and preserved erectile function.

See all 7 questions from this masterclass →

Book a Consultation with Dr. Shafiq Ahmad

Book on WhatsApp

Or message us on WhatsApp: +91 98182 98669

Frequently Asked Questions

What is the comparison between orchidectomy and radical prostatectomy?

There is no real comparison — they serve different purposes. Orchidectomy is chosen for metastatic (stage 4) disease, such as a patient with multiple spinal metastases who cannot walk. Radical prostatectomy is chosen for patients whose expected lifespan is more than 10 years, who are fit for surgery, and who have organ-confined, locally advanced, or oligometastatic disease (one or two spots on PSMA PET). Orchidectomy is simply a form of androgen deprivation — nowadays we hardly do it routinely because injectable or oral androgen deprivation therapy is available; it's now used mainly for stage 4 disease.

What are the ultrasound findings that differentiate chronic prostatitis from prostate cancer, and can tumour lysis syndrome occur at the initiation of radiotherapy?

On Doppler ultrasound, chronic prostatitis typically shows uniformly increased vascularity across the whole prostate, whereas prostate cancer shows increased vascularity at one specific point, such as a nodule. However, we don't rely on ultrasound alone to distinguish the two — it comes down to clinical judgement, PSA value, and age, since chronic prostatitis is a disease of younger, sexually active men in their 40s to early 50s, while prostate cancer is a disease of old age; I would be hesitant to diagnose chronic prostatitis in a 60-65 year old with a PSA of 10 and urinary symptoms — that points toward BPH with a suspicion of prostate cancer to rule out. On tumour lysis syndrome: yes, it can happen with any treatment — radiotherapy or chemotherapy — in any tumour, most often solid tumours; it is not specific to prostate cancer.

To reconfirm on orchidectomy — nowadays it's not done routinely for prostate cancer when androgen deprivation drugs are available, and it is done only where those drugs are not available — is that right?

Yes, that's correct. Orchidectomy is a cost-effective, one-time procedure, and increasingly patients in developing countries are also getting health insurance that covers the ongoing medications, so when it comes to overall treatment, orchidectomy can even be considered superior in efficacy compared to injectable treatment, and there's no harm in doing it. However, losing a testicle is a point of real psychological impact for a man, so if a patient can afford it or the treatment is available, I would suggest androgen deprivation therapy via injections or medication as preferable — orchidectomy remains a well-suited procedure specifically for patients with stage 4 disease.

I have a patient with bilateral paraparesis, power of the lower limbs 2/5 bilaterally, a hard prostate on digital rectal exam, and PSA greater than 100 — advanced prostate cancer with spinal metastasis causing the paraparesis was considered. In our setup we don't have hormonal therapy, so we did a bilateral orchidectomy, and the patient improved and was able to walk within five days. On follow-up he developed excessive heat, central abdominal obesity, breast enlargement, and high TSH. How should this hormonal disturbance be managed?

What you're describing is the androgen depletion syndrome — you have abolished testosterone, so the patient develops post-menopausal-type symptoms. In our practice, for patients who have undergone androgen deprivation, we educate them not to panic, start gabapentin and sometimes an anti-anxiety medication, and for central obesity and related issues advise calcium and vitamin D supplements, a high-protein, low-fat diet, regular exercise, and sunlight exposure, since bones become fragile and there is increased risk of coronary artery disease and hypertension. We sometimes also use denosumab if the patient is very incapacitated by hot flashes and sweating. You did the right thing for your patient — surgical castration is the most practical option where injectable androgen analogues or antagonists aren't reliably available.

In a patient with total PSA greater than 10, a digital rectal exam that does not show nodularity, and no access to biopsy, what would be your recommendation for management options?

False positivity of PSA is very common, so I would follow this patient regularly, first checking for infection. I would repeat the PSA after 6 weeks — if the high PSA was due to infection, a course of antibiotics should show a downward trend by then; if it doesn't trend down, you should have a high suspicion of prostate cancer. You can also check the free-to-total PSA ratio — if it's less than 25%, that supports the diagnosis. If the DRE is normal and there's no biopsy facility, you can follow the patient for a year and check PSA velocity — if it goes beyond 0.75 per year, refer to a centre with TRUS-guided biopsy or MRI facilities. With a PSA of 10-20, there is roughly a 10-30% chance of harbouring prostate cancer, so this should be investigated further rather than dismissed.

How can a doctor outside India get a second opinion on a prostate cancer case?

Referring doctors can share case files and reports through a structured pathway, sometimes called an online OPD or connect clinic model, so the case can be reviewed remotely by the treating team in India.

What determines whether a prostate cancer case needs specialist review?

Referring doctors first assess whether a case meets the complexity criteria that warrant specialist input before relevant reports are shared for remote review.

What happens once a prostate cancer case is confirmed to need specialist attention?

A video consultation can be arranged between the specialist in India and the patient, with the local doctor invited to join, so the patient benefits from combined expertise without needing to travel unnecessarily.

Why does a structured second opinion pathway matter for prostate cancer patients?

It allows patients to access expert guidance before committing to travel, helping ensure a visit is genuinely warranted while the local doctor remains involved in ongoing care.

Need Expert Medical Guidance?

Connect with leading specialists through the Jivo Healthcare network for personalized advice.

Get Expert Opinion